- Investors & Media
- Investors & Media
- Contact Us
The company announced interim results from the Company's Phase 2 trial of intravenous Alpha-1 Antitrypsin (IV AAT) for the prevention of lung transplant rejection.
Kamada announced a collaboration with the Mount Sinai Acute GvHD International Consortium (MAGIC) to conduct a proof-of-concept clinical trial assessing the safety and preliminary efficacy of Kamada's Alpha- 1-Antitrypsin (AAT) as preemptive therapy for patients at high-risk for the development of steroidrefractory acute GvHD (SR-aGvHD).
Kamada announced that the Company and Chiesi Farmaceutici S.p.A., a fully integrated European Pharmaceutical company focused on respiratory disease and special care products, have mutually agreed to terminate the parties' European distribution agreement related to Kamada's inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Kamada announced today that it has signed a supply agreement with an undisclosed international organization for KamRAB [rabies immune globulin (Human)].
Kamada announced financial results for the three and nine months ended September 30, 2017.
On October 26, 2017, Kamada Ltd. announced the 2017 Annual General Meeting of shareholders of the Company to be held on November 30, 2017.
Kamada announced today that it will release financial results for the third quarter ended September 30, 2017, prior to the open of the U.S. financial markets on Monday, November 13.
Efficacy trend was demonstrated in the pre-determined subgroup of patients between the ages of 12 to 18, treated with the higher dose of 120mg/kg. The positive trend was observed in this age group for all three key efficacy measures of Type-1 Diabetes.
Listen to Kamada's CEO, Mr. Amir London, presenting the company's current commercial portfolio and significant growth, as well as the clinical pipeline and future value creating milestones. Link to audio…
Kamada announced that Gil Efron, Deputy Chief Executive Officer (Deputy CEO) & Chief Financial Officer (CFO) recently informed the Company of his plan to leave at the end of the year.